Stock Analysis on Net
Stock Analysis on Net

Gilead Sciences Inc. (NASDAQ:GILD)

Analysis of Short-term (Operating) Activity Ratios 
Quarterly Data

Microsoft Excel

Short-term Activity Ratios (Summary)

Gilead Sciences Inc., short-term (operating) activity ratios (quarterly data)

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Turnover Ratios
Inventory turnover 3.18 3.21 3.51 3.47 3.40 3.55 3.66 3.62 3.33 3.59 3.64 3.49 3.45 3.57 3.75 4.71 4.50 4.50
Receivables turnover 5.90 6.17 5.89 5.60 6.01 6.51 6.47 6.14 5.92 5.84 5.78 5.68 6.43 6.43 5.65 6.16 6.60 7.18
Payables turnover 9.22 9.52 8.72 7.66 10.65 8.47 7.50 7.49 12.57 10.69 11.81 9.90 9.06 8.99 6.25 11.22 11.89 11.43
Working capital turnover 10.20 3.19 4.43 5.12 8.14 6.27 3.99 9.22 17.98 26.58 5.61 6.74 84.15 9.14 8.42 8.56 6.87 6.68
Average No. Days
Average inventory processing period 115 114 104 105 108 103 100 101 110 102 100 105 106 102 97 78 81 81
Add: Average receivable collection period 62 59 62 65 61 56 56 59 62 62 63 64 57 57 65 59 55 51
Operating cycle 177 173 166 170 169 159 156 160 172 164 163 169 163 159 162 137 136 132
Less: Average payables payment period 40 38 42 48 34 43 49 49 29 34 31 37 40 41 58 33 31 32
Cash conversion cycle 137 135 124 122 135 116 107 111 143 130 132 132 123 118 104 104 105 100

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).


An analysis of operating activity ratios reveals a general trend of declining efficiency in the management of short-term assets from March 2022 through June 2026. The overall operational efficiency is characterized by a lengthening of the time required to convert inputs into cash, as evidenced by the steady increase in the operating cycle and the cash conversion cycle.

Inventory and Receivables Efficiency
Inventory turnover demonstrates a persistent downward trajectory, decreasing from 4.50 in March 2022 to 3.18 by June 2026. This decline is mirrored in the average inventory processing period, which expanded from 81 days to 115 days, suggesting a slower turnover of stock. Receivables turnover remained relatively more stable, fluctuating between a high of 7.18 and a low of 5.60, with the average collection period generally oscillating between 51 and 65 days.
Payables and Working Capital Dynamics
Payables turnover exhibits significant volatility, with values ranging from 6.25 to 12.57, indicating inconsistent patterns in the settlement of short-term obligations. The average payables payment period showed no linear trend, varying between 29 and 58 days. Working capital turnover displayed extreme fluctuations, notably peaking at 84.15 in June 2023 and 26.58 in March 2024, before stabilizing at a lower level of 10.20 by June 2026.
Operational Cycle Analysis
The operating cycle shows a clear upward trend, extending from 132 days in March 2022 to 177 days by June 2026. This expansion is primarily driven by the increase in the inventory processing period. Consequently, the cash conversion cycle also increased from 100 days to 137 days over the observed period, indicating that capital remains tied up in operating activities for a longer duration.

AI Ask an analyst for more


Turnover Ratios


Average No. Days


Inventory Turnover

Gilead Sciences Inc., inventory turnover calculation (quarterly data)

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Cost of goods sold 1,579 1,445 1,624 1,569 1,501 1,540 1,581 1,574 1,544 1,552 2,090 1,565 1,442 1,401 1,396 1,395 1,442 1,424
Inventories 1,953 1,914 1,774 1,785 1,825 1,759 1,710 1,869 2,026 1,853 1,787 1,663 1,633 1,576 1,507 1,463 1,494 1,482
Short-term Activity Ratio
Inventory turnover1 3.18 3.21 3.51 3.47 3.40 3.55 3.66 3.62 3.33 3.59 3.64 3.49 3.45 3.57 3.75 4.71 4.50 4.50
Benchmarks
Inventory Turnover, Competitors2
AbbVie Inc. 3.58 3.65 3.68 3.65 3.42 3.71 4.04 4.09 4.86 4.83 4.98 4.74 4.30 4.53 4.87 5.54 4.99 4.96
Amgen Inc. 1.87 1.91 1.93 1.92 1.88 1.88 1.84 1.75 1.42 1.14 0.89 1.41 1.38 1.31 1.30 1.34 1.40 1.48
Bristol-Myers Squibb Co. 5.36 5.20 5.18 5.31 5.18 5.28 5.46 3.57 3.72 3.70 4.02 4.33 4.39 3.93 4.33 4.77 4.59 4.55
Danaher Corp. 3.20 3.90 4.04 3.67 3.60 3.79 4.15 3.60 3.59 3.73 3.80 3.53 3.58 3.50 4.03 3.80 3.71 3.87
Eli Lilly & Co. 0.79 0.85 0.80 0.83 0.84 0.96 1.11 1.05 1.16 1.17 1.23 1.40 1.37 1.36 1.54 1.86 1.79 1.93
Johnson & Johnson 2.08 2.13 2.13 2.08 2.17 2.24 2.21 2.15 2.20 2.32 2.37 2.46 2.23 2.36 2.49 2.68 2.69 2.77
Merck & Co. Inc. 2.90 2.65 2.46 2.27 2.25 2.43 2.49 2.45 2.39 2.42 2.54 2.63 2.66 2.72 2.95 3.10 3.06 2.74
Pfizer Inc. 1.72 1.57 1.51 1.46 1.52 1.60 1.65 1.66 2.05 2.15 2.45 2.65 2.31 3.07 3.82 3.62 3.66 3.67
Regeneron Pharmaceuticals Inc. 0.76 0.74 0.66 0.64 0.64 0.63 0.64 0.64 0.65 0.66 0.70 0.72 0.69 0.67 0.65 0.83 0.96 1.27
Thermo Fisher Scientific Inc. 4.87 4.87 4.85 4.47 4.57 4.82 5.06 4.62 4.83 4.93 5.06 4.83 4.64 4.62 4.60 4.29 4.03 3.87
Vertex Pharmaceuticals Inc. 1.00 0.95 0.98 0.99 1.06 1.14 1.27 1.37 1.53 1.65 1.71 1.71 1.90 2.06 2.35 2.69 2.70 2.83

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q2 2026 Calculation
Inventory turnover = (Cost of goods soldQ2 2026 + Cost of goods soldQ1 2026 + Cost of goods soldQ4 2025 + Cost of goods soldQ3 2025) ÷ Inventories
= (1,579 + 1,445 + 1,624 + 1,569) ÷ 1,953 = 3.18

2 Click competitor name to see calculations.


An overall downward trend in inventory turnover is evident over the observed period, indicating a deceleration in the rate at which inventory is cycled through the business. The turnover ratio declined from a peak of 4.71 in September 2022 to a low of 3.18 by June 2026, reflecting a decrease in operational efficiency regarding inventory management.

Inventory Turnover Ratio Trends
The ratio exhibited relative strength throughout the first half of 2022, maintaining levels between 4.50 and 4.71. However, a significant shift occurred in December 2022, where the ratio dropped to 3.75 and remained largely within a range of 3.33 to 3.66 through mid-2024. The most recent quarters show a further deterioration, with the ratio falling to 3.21 in March 2026 and 3.18 in June 2026.
Inventory Asset Accumulation
A primary driver of the declining turnover is the steady increase in total inventories. Assets grew from 1,482 million in March 2022 to a peak of 2,026 million in June 2024. While there was a temporary reduction toward the end of 2024, inventories climbed again to 1,953 million by June 2026. The growth in inventory levels has consistently outpaced the growth in the cost of goods sold, leading to a lower turnover rate.
Cost of Goods Sold (COGS) Analysis
COGS remained relatively stable for the majority of the period, typically fluctuating between 1.4 billion and 1.6 billion. A notable anomaly occurred in December 2023, where COGS spiked to 2,090 million. This surge provided a temporary lift to the inventory turnover ratio (3.64) during that quarter, preventing a sharper decline despite rising inventory levels at that time.
Operational Implications
The divergence between rising inventory levels and stagnant COGS suggests a potential increase in safety stock, anticipation of future demand, or a slowdown in product movement. The persistent decline in the ratio through 2026 indicates that the company is holding inventory for longer periods than it did in 2022.

AI Ask an analyst for more


Receivables Turnover

Gilead Sciences Inc., receivables turnover calculation (quarterly data)

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Product sales 7,627 6,946 7,903 7,345 7,054 6,613 7,536 7,515 6,912 6,647 7,070 6,994 6,564 6,306 7,332 6,978 6,138 6,534
Accounts receivable, net 5,055 4,741 4,913 5,095 4,781 4,388 4,420 4,587 4,663 4,669 4,660 4,790 4,229 4,162 4,777 4,354 4,118 3,787
Short-term Activity Ratio
Receivables turnover1 5.90 6.17 5.89 5.60 6.01 6.51 6.47 6.14 5.92 5.84 5.78 5.68 6.43 6.43 5.65 6.16 6.60 7.18
Benchmarks
Receivables Turnover, Competitors2
AbbVie Inc. 4.66 5.03 4.86 4.67 4.62 4.60 5.16 4.84 4.69 4.55 4.87 4.83 4.88 4.95 5.16 5.38 5.10 5.29
Amgen Inc. 3.55 3.88 3.67 4.06 3.85 4.03 4.72 4.26 4.26 4.16 3.70 4.17 4.34 4.34 4.46 4.60 4.62 4.81
Danaher Corp. 6.33 6.49 6.28 6.46 6.74 6.79 6.75 6.77 7.15 7.02 6.09 6.15 6.64 6.89 6.40 7.09 6.81 6.87
Eli Lilly & Co. 3.97 3.92 3.67 3.69 3.76 4.07 4.09 3.97 3.53 4.56 3.75 3.93 3.93 3.68 4.14 4.35 4.57 4.64
Johnson & Johnson 5.14 5.44 5.48 5.23 5.08 5.58 5.98 5.42 5.48 5.73 5.73 5.91 5.36 5.65 5.88 6.04 5.92 6.08
Merck & Co. Inc. 5.30 5.39 5.52 5.30 5.37 5.92 6.24 5.55 5.37 5.40 5.81 5.71 5.29 5.56 6.27 6.22 5.93 5.49
Pfizer Inc. 5.10 5.03 5.27 4.40 5.29 5.27 5.55 4.18 4.93 5.09 5.33 6.25 7.66 7.57 9.16 6.21 6.68 6.99
Regeneron Pharmaceuticals Inc. 2.37 2.60 2.50 2.51 2.53 2.53 2.29 2.27 2.36 2.51 2.31 2.35 2.47 2.42 2.28 2.47 2.76 3.41
Thermo Fisher Scientific Inc. 4.90 4.91 5.01 4.91 5.03 5.07 5.23 5.13 5.33 5.36 5.21 5.19 5.43 5.53 5.53 5.76 5.53 5.21
Vertex Pharmaceuticals Inc. 5.90 6.12 5.85 6.02 6.03 6.15 6.85 6.07 6.24 5.68 6.31 6.27 6.11 5.95 6.19 6.28 6.26 6.15

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q2 2026 Calculation
Receivables turnover = (Product salesQ2 2026 + Product salesQ1 2026 + Product salesQ4 2025 + Product salesQ3 2025) ÷ Accounts receivable, net
= (7,627 + 6,946 + 7,903 + 7,345) ÷ 5,055 = 5.90

2 Click competitor name to see calculations.


The receivables turnover ratio demonstrates a period of initial contraction followed by a phase of relative stabilization characterized by cyclical fluctuations. From March 2022 to December 2022, the ratio declined from 7.18 to 5.65, indicating a reduction in the efficiency of collecting outstanding product sales receivables during that timeframe.

Correlation Between Sales and Receivables
Product sales fluctuated throughout the period, reaching a peak of 7,903 million in December 2025. Concurrently, net accounts receivable grew from 3,787 million in March 2022 to 5,055 million by June 2026. The tendency for receivables to increase in tandem with sales volume has prevented the turnover ratio from returning to the levels seen in early 2022.
Analysis of Turnover Fluctuations
A recovery in collection efficiency was observed in the first half of 2023, where the ratio reached 6.43. This was followed by a decline to 5.68 by September 2023. The ratio showed a steady upward trend throughout 2024, peaking at 6.51 in March 2025, before experiencing another dip to 5.60 in September 2025. The most recent data indicates a slight recovery to 5.90 by June 2026.
Overall Efficiency Trend
A comparative analysis between the initial period and the final reporting date reveals a net decrease in turnover efficiency, moving from 7.18 to 5.90. The ratio has transitioned from a higher baseline in early 2022 to a stabilized operational range typically oscillating between 5.6 and 6.5.

AI Ask an analyst for more


Payables Turnover

Gilead Sciences Inc., payables turnover calculation (quarterly data)

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Cost of goods sold 1,579 1,445 1,624 1,569 1,501 1,540 1,581 1,574 1,544 1,552 2,090 1,565 1,442 1,401 1,396 1,395 1,442 1,424
Accounts payable 674 645 715 808 582 737 833 903 537 622 550 586 622 627 905 614 565 583
Short-term Activity Ratio
Payables turnover1 9.22 9.52 8.72 7.66 10.65 8.47 7.50 7.49 12.57 10.69 11.81 9.90 9.06 8.99 6.25 11.22 11.89 11.43
Benchmarks
Payables Turnover, Competitors2
Amgen Inc. 4.05 4.02 5.09 4.29 4.12 5.25 6.74 5.99 5.01 6.10 5.32 5.22 5.67 4.97 4.08 5.30 5.09 4.65
Bristol-Myers Squibb Co. 3.53 3.38 3.90 3.42 2.61 3.52 3.88 3.43 3.05 3.12 3.28 3.75 3.38 3.20 3.33 3.82 3.41 3.25
Danaher Corp. 5.72 5.68 5.45 5.78 5.62 5.57 5.52 6.04 5.84 5.88 5.58 5.63 5.82 5.68 5.45 5.61 5.00 5.04
Eli Lilly & Co. 2.16 2.47 2.05 2.37 2.27 2.61 2.61 2.70 2.56 2.88 2.73 2.81 2.65 3.07 3.43 4.24 4.21 5.24
Johnson & Johnson 3.41 2.96 2.52 3.06 3.07 2.97 2.66 3.03 3.03 3.23 2.76 3.29 2.75 3.05 2.66 3.08 3.15 3.26
Merck & Co. Inc. 4.70 4.44 3.72 3.53 3.82 3.98 3.72 4.26 4.39 4.48 4.11 4.59 4.58 4.34 4.08 5.16 4.86 4.25
Pfizer Inc. 3.73 3.72 3.07 3.32 3.44 3.30 3.17 3.67 4.60 4.19 3.72 5.07 3.92 4.78 5.04 5.49 6.17 6.66
Regeneron Pharmaceuticals Inc. 2.03 2.24 2.24 2.30 2.83 2.84 2.50 3.87 3.32 2.67 2.99 3.43 3.14 2.69 2.65 3.74 4.00 5.39
Thermo Fisher Scientific Inc. 8.39 8.00 7.27 8.23 8.53 8.25 8.18 9.63 9.85 9.91 8.97 10.41 10.82 9.35 7.67 9.93 8.84 7.96
Vertex Pharmaceuticals Inc. 4.10 3.44 3.58 3.83 3.59 3.49 3.71 3.73 4.27 3.81 3.46 3.13 3.16 3.41 3.55 8.23 5.01 5.52

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q2 2026 Calculation
Payables turnover = (Cost of goods soldQ2 2026 + Cost of goods soldQ1 2026 + Cost of goods soldQ4 2025 + Cost of goods soldQ3 2025) ÷ Accounts payable
= (1,579 + 1,445 + 1,624 + 1,569) ÷ 674 = 9.22

2 Click competitor name to see calculations.


The payables turnover ratio exhibits significant volatility over the analyzed period, reflecting fluctuations in the timing of supplier payments relative to the cost of goods sold. While the ratio frequently oscillates between approximately 7.5 and 12.6, there are distinct periods of contraction and recovery that correspond with fluctuations in accounts payable balances.

Ratio Volatility and Periodic Lows
Significant troughs in the payables turnover ratio are observed in December 2022 (6.25), September 2024 (7.49), and June 2025 (7.66). These declines correlate with substantial increases in accounts payable—reaching 905 million US dollars in December 2022 and 903 million US dollars in September 2024—indicating periods where supplier obligations remained outstanding for longer durations.
Recovery Phases and Peak Efficiency
Peaks in turnover efficiency occurred in June 2022 (11.89) and December 2023 (11.81). During these intervals, lower balances of accounts payable relative to the cost of goods sold indicate a more rapid settlement of supplier obligations.
Relationship with Cost of Goods Sold
The cost of goods sold remained relatively stable between 1.4 billion and 1.6 billion US dollars for the majority of the period, with a notable spike to 2.09 billion US dollars in December 2023. Interestingly, the payables turnover ratio reached one of its highest points during this spike, suggesting that the increase in operating costs did not result in a corresponding increase in outstanding payables.
Stabilization Trends
In the latter part of the analysis, from March 2026 through June 2026, the ratio demonstrates a narrowing range, moving from 9.52 to 9.22. This suggests a transition toward a more consistent and predictable cycle of procurement and payment.

AI Ask an analyst for more


Working Capital Turnover

Gilead Sciences Inc., working capital turnover calculation (quarterly data)

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Current assets 13,945 18,641 18,342 17,874 14,718 16,901 19,173 14,779 12,317 14,041 16,085 15,980 14,287 13,456 14,443 13,554 13,175 12,629
Less: Current liabilities 11,020 9,476 11,813 12,298 11,189 12,344 12,004 11,725 10,781 13,015 11,280 11,945 13,964 10,528 11,237 10,423 9,220 8,558
Working capital 2,925 9,165 6,529 5,576 3,529 4,557 7,169 3,054 1,536 1,026 4,805 4,035 323 2,928 3,206 3,131 3,955 4,071
 
Product sales 7,627 6,946 7,903 7,345 7,054 6,613 7,536 7,515 6,912 6,647 7,070 6,994 6,564 6,306 7,332 6,978 6,138 6,534
Short-term Activity Ratio
Working capital turnover1 10.20 3.19 4.43 5.12 8.14 6.27 3.99 9.22 17.98 26.58 5.61 6.74 84.15 9.14 8.42 8.56 6.87 6.68
Benchmarks
Working Capital Turnover, Competitors2
AbbVie Inc.
Amgen Inc. 3.83 5.44 9.85 5.66 5.35 8.36 5.40 4.83 5.19 3.39 2.25 0.81 0.84 0.82 3.82 2.52 3.67 4.34
Bristol-Myers Squibb Co. 4.81 5.84 7.83 6.20 8.09 6.87 7.79 8.49 12.50 15.56 4.60 10.47 5.53 5.55 8.30 5.75 4.92 6.24
Danaher Corp. 4.76 3.83 4.13 7.39 5.71 8.27 8.85 8.73 8.10 3.60 4.22 2.18 3.08 3.81 4.20 5.00 5.43 5.91
Eli Lilly & Co. 4.71 3.97 3.19 2.71 4.92 4.38 10.32 6.06 12.62 5.45 31.79 12.21 5.77 31.84 14.71 19.45 8.19
Johnson & Johnson 20.07 66.14 62.88 24.63 284.99 6.10 15.94 58.86 22.29 10.35 11.81 9.37 14.06 23.02 4.88 5.02 5.57
Merck & Co. Inc. 7.44 8.15 4.28 3.39 5.77 6.19 6.19 5.86 5.14 9.68 9.29 6.69 8.86 5.63 5.16 5.58 6.39 6.09
Pfizer Inc. 7.31 7.47 10.58 6.08 10.68 6.64 8.64 5,036.00 29.17 1.62 2.03 6.89 11.00 3.83 5.05 6.10
Regeneron Pharmaceuticals Inc. 1.20 1.14 1.05 1.05 1.08 1.01 0.97 0.88 0.87 0.86 0.82 0.87 0.92 0.90 0.96 1.09 1.14 1.46
Thermo Fisher Scientific Inc. 5.59 5.87 3.30 5.90 3.64 4.20 4.87 4.61 3.96 4.38 4.05 4.86 7.40 10.13 5.46 5.40 6.03 6.13
Vertex Pharmaceuticals Inc. 1.46 1.56 1.64 1.92 1.82 1.78 1.83 1.82 1.92 1.07 0.93 0.87 0.90 0.93 0.85 0.90 0.93 0.97

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q2 2026 Calculation
Working capital turnover = (Product salesQ2 2026 + Product salesQ1 2026 + Product salesQ4 2025 + Product salesQ3 2025) ÷ Working capital
= (7,627 + 6,946 + 7,903 + 7,345) ÷ 2,925 = 10.20

2 Click competitor name to see calculations.


The analysis of working capital turnover reveals significant volatility driven primarily by fluctuations in working capital levels rather than changes in revenue generation. While product sales have remained relatively stable throughout the observed period, the efficiency of working capital utilization has experienced extreme variances, suggesting inconsistent short-term asset and liability management.

Product Sales Stability
Product sales demonstrate a consistent performance range, fluctuating between a minimum of 6,138 million USD in June 2022 and a maximum of 7,903 million USD in December 2025. This stability indicates that the numerator of the turnover ratio remains steady, meaning any dramatic shifts in the turnover ratio are attributable to changes in the working capital base.
Working Capital Volatility
Working capital exhibits erratic behavior, characterized by sharp contractions and expansions. A significant reduction is noted in June 2023, where working capital dropped to 323 million USD. Conversely, a strong upward trend emerged toward the end of the period, peaking at 9,165 million USD by March 2026. This volatility suggests periodic shifts in the company's liquidity position or strategic changes in managing current assets and liabilities.
Turnover Ratio Anomalies
Extreme spikes in the working capital turnover ratio are observed in June 2023 (84.15) and March 2024 (26.58). These outliers are direct results of the sharp decreases in working capital during those specific quarters. Such high ratios typically indicate an extremely lean operation or a temporary deficit in working capital that allows for a mathematically inflated turnover figure.
Long-term Efficiency Trend
From December 2023 through March 2026, a general downward trend in turnover efficiency is evident. The ratio declined from 5.61 to a low of 3.19. This decline correlates with the steady expansion of working capital, indicating that a larger volume of capital is being deployed to support the same level of product sales, which represents a decrease in short-term operational efficiency.

AI Ask an analyst for more


Average Inventory Processing Period

Gilead Sciences Inc., average inventory processing period calculation (quarterly data)

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data
Inventory turnover 3.18 3.21 3.51 3.47 3.40 3.55 3.66 3.62 3.33 3.59 3.64 3.49 3.45 3.57 3.75 4.71 4.50 4.50
Short-term Activity Ratio (no. days)
Average inventory processing period1 115 114 104 105 108 103 100 101 110 102 100 105 106 102 97 78 81 81
Benchmarks (no. days)
Average Inventory Processing Period, Competitors2
AbbVie Inc. 102 100 99 100 107 98 90 89 75 75 73 77 85 81 75 66 73 74
Amgen Inc. 195 191 189 190 194 195 199 209 257 321 411 259 265 279 281 272 260 247
Bristol-Myers Squibb Co. 68 70 70 69 70 69 67 102 98 99 91 84 83 93 84 76 79 80
Danaher Corp. 114 94 90 99 101 96 88 101 102 98 96 104 102 104 91 96 98 94
Eli Lilly & Co. 463 428 454 441 435 379 329 349 316 312 298 261 267 268 237 196 204 189
Johnson & Johnson 176 172 171 176 168 163 165 169 166 158 154 149 164 155 147 136 136 132
Merck & Co. Inc. 126 138 148 160 162 150 147 149 153 151 144 139 137 134 124 118 119 133
Pfizer Inc. 212 232 242 251 239 229 222 219 178 170 149 138 158 119 95 101 100 99
Regeneron Pharmaceuticals Inc. 479 491 556 571 570 582 572 573 562 553 519 508 532 549 562 440 379 287
Thermo Fisher Scientific Inc. 75 75 75 82 80 76 72 79 76 74 72 76 79 79 79 85 91 94
Vertex Pharmaceuticals Inc. 365 384 373 369 345 320 287 267 238 222 214 213 192 177 156 136 135 129

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q2 2026 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ 3.18 = 115

2 Click competitor name to see calculations.


The analysis of operating activity ratios reveals a consistent elongation of the inventory cycle from March 2022 through June 2026. This trend is characterized by a steady increase in the number of days required to process inventory, which directly correlates with a decline in the overall inventory turnover ratio.

Average Inventory Processing Period Trends
The processing period began at a baseline of 81 days in the first half of 2022. A significant shift occurred in the latter half of 2022, with the period increasing to 97 days by December 31. Throughout 2023 and 2024, the duration remained elevated, generally fluctuating between 100 and 110 days. A further upward trajectory is observed in the first half of 2026, where the period reached its peak at 115 days by June 30, 2026.
Inventory Turnover Correlation
The inventory turnover ratio demonstrates a strong inverse correlation with the processing period. The turnover ratio peaked at 4.71 in September 2022 before entering a gradual decline. By June 30, 2026, the turnover ratio decreased to 3.18, marking the lowest point in the analyzed period. This reduction in the turnover rate indicates a lower frequency of inventory replacement, which accounts for the increase in the number of days inventory remains in processing.
Operational Efficiency Insights
The expansion of the inventory cycle from 81 days to 115 days suggests a slowing of goods movement through the supply chain. The persistent increase in the processing period indicates that working capital is tied up in inventory for longer durations. This pattern may reflect shifts in demand, changes in inventory management strategies, or a decrease in the efficiency of converting inventory into sales.

AI Ask an analyst for more


Average Receivable Collection Period

Gilead Sciences Inc., average receivable collection period calculation (quarterly data)

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data
Receivables turnover 5.90 6.17 5.89 5.60 6.01 6.51 6.47 6.14 5.92 5.84 5.78 5.68 6.43 6.43 5.65 6.16 6.60 7.18
Short-term Activity Ratio (no. days)
Average receivable collection period1 62 59 62 65 61 56 56 59 62 62 63 64 57 57 65 59 55 51
Benchmarks (no. days)
Average Receivable Collection Period, Competitors2
AbbVie Inc. 78 73 75 78 79 79 71 75 78 80 75 76 75 74 71 68 72 69
Amgen Inc. 103 94 99 90 95 91 77 86 86 88 99 88 84 84 82 79 79 76
Danaher Corp. 58 56 58 56 54 54 54 54 51 52 60 59 55 53 57 51 54 53
Eli Lilly & Co. 92 93 99 99 97 90 89 92 103 80 97 93 93 99 88 84 80 79
Johnson & Johnson 71 67 67 70 72 65 61 67 67 64 64 62 68 65 62 60 62 60
Merck & Co. Inc. 69 68 66 69 68 62 58 66 68 68 63 64 69 66 58 59 62 66
Pfizer Inc. 72 73 69 83 69 69 66 87 74 72 69 58 48 48 40 59 55 52
Regeneron Pharmaceuticals Inc. 154 140 146 146 144 144 160 161 155 146 158 156 148 151 160 148 132 107
Thermo Fisher Scientific Inc. 74 74 73 74 73 72 70 71 68 68 70 70 67 66 66 63 66 70
Vertex Pharmaceuticals Inc. 62 60 62 61 61 59 53 60 58 64 58 58 60 61 59 58 58 59

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q2 2026 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ 5.90 = 62

2 Click competitor name to see calculations.


The analysis of short-term operating activity reveals a period of fluctuation in the efficiency of receivables management. Between March 2022 and June 2026, there is an observable shift in the time required to collect outstanding payments, characterized by an initial expansion of the collection period followed by a phase of relative volatility and stabilization.

Receivables Turnover Trends
The turnover ratio experienced a contraction from a peak of 7.18 in March 2022 to a low of 5.65 by December 2022. Subsequent quarters showed a pattern of volatility, with a recovery to 6.43 in mid-2023, followed by a period of oscillation between 5.60 and 6.51 through the end of 2024. The most recent figures indicate that the ratio has stabilized at a lower level than the 2022 baseline, ending at 5.90 in June 2026.
Average Receivable Collection Period Analysis
The collection period demonstrates a consistent inverse correlation with the turnover ratios. The period expanded from 51 days in March 2022 to a high of 65 days by December 2022. Although a temporary improvement occurred in the first half of 2023, where the period dropped to 57 days, the duration generally remained elevated, fluctuating between 56 and 65 days for the remainder of the analyzed timeframe. The cycle concluded at 62 days in June 2026.
Operational Efficiency Insights
The overall trend indicates a systemic increase in the average time taken to convert receivables into cash. The transition from a 51-day cycle to a 62-day cycle suggests a moderate deceleration in the cash conversion process over the long term. However, the absence of a linear upward trend and the occurrence of periodic reductions suggest that credit terms or collection efforts are being adjusted to maintain the collection period within a range of approximately 56 to 65 days.

AI Ask an analyst for more


Operating Cycle

Gilead Sciences Inc., operating cycle calculation (quarterly data)

No. days

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data
Average inventory processing period 115 114 104 105 108 103 100 101 110 102 100 105 106 102 97 78 81 81
Average receivable collection period 62 59 62 65 61 56 56 59 62 62 63 64 57 57 65 59 55 51
Short-term Activity Ratio
Operating cycle1 177 173 166 170 169 159 156 160 172 164 163 169 163 159 162 137 136 132
Benchmarks
Operating Cycle, Competitors2
AbbVie Inc. 180 173 174 178 186 177 161 164 153 155 148 153 160 155 146 134 145 143
Amgen Inc. 298 285 288 280 289 286 276 295 343 409 510 347 349 363 363 351 339 323
Danaher Corp. 172 150 148 155 155 150 142 155 153 150 156 163 157 157 148 147 152 147
Eli Lilly & Co. 555 521 553 540 532 469 418 441 419 392 395 354 360 367 325 280 284 268
Johnson & Johnson 247 239 238 246 240 228 226 236 233 222 218 211 232 220 209 196 198 192
Merck & Co. Inc. 195 206 214 229 230 212 205 215 221 219 207 203 206 200 182 177 181 199
Pfizer Inc. 284 305 311 334 308 298 288 306 252 242 218 196 206 167 135 160 155 151
Regeneron Pharmaceuticals Inc. 633 631 702 717 714 726 732 734 717 699 677 664 680 700 722 588 511 394
Thermo Fisher Scientific Inc. 149 149 148 156 153 148 142 150 144 142 142 146 146 145 145 148 157 164
Vertex Pharmaceuticals Inc. 427 444 435 430 406 379 340 327 296 286 272 271 252 238 215 194 193 188

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q2 2026 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= 115 + 62 = 177

2 Click competitor name to see calculations.


The analyzed period is characterized by a progressive elongation of the operating cycle, reflecting an increase in the time required to convert investments in inventory and receivables into cash.

Average Inventory Processing Period
An upward trend is evident in the inventory processing period, which rose from 81 days in March 2022 to 115 days by June 2026. A notable shift occurred between September 2022 and March 2023, where the period expanded from 78 days to 102 days. Following this shift, the metric remained consistently above 100 days, indicating a slower movement of stock through the production and sales pipeline.
Average Receivable Collection Period
The receivable collection period exhibits moderate volatility with a slight long-term increase. Starting at 51 days in March 2022, the period peaked at 65 days in December 2022 and June 2025, before settling at 62 days by June 2026. While less impactful than inventory movements, the general increase suggests a marginal decline in the efficiency of credit collections.
Operating Cycle
The overall operating cycle expanded from 132 days in March 2022 to 177 days in June 2026. This expansion is primarily driven by the increase in the average inventory processing period. A significant jump in cycle duration is observed between September 2022 and December 2022, where the cycle moved from 137 days to 162 days, establishing a higher baseline of duration that persisted through the subsequent quarters.

The cumulative effect of these trends indicates a reduction in short-term operating efficiency, as the total duration of the operating cycle increased by 45 days over the observed timeframe.

AI Ask an analyst for more


Average Payables Payment Period

Gilead Sciences Inc., average payables payment period calculation (quarterly data)

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data
Payables turnover 9.22 9.52 8.72 7.66 10.65 8.47 7.50 7.49 12.57 10.69 11.81 9.90 9.06 8.99 6.25 11.22 11.89 11.43
Short-term Activity Ratio (no. days)
Average payables payment period1 40 38 42 48 34 43 49 49 29 34 31 37 40 41 58 33 31 32
Benchmarks (no. days)
Average Payables Payment Period, Competitors2
Amgen Inc. 90 91 72 85 89 70 54 61 73 60 69 70 64 73 90 69 72 78
Bristol-Myers Squibb Co. 103 108 94 107 140 104 94 106 120 117 111 97 108 114 109 96 107 112
Danaher Corp. 64 64 67 63 65 66 66 60 63 62 65 65 63 64 67 65 73 72
Eli Lilly & Co. 169 148 178 154 161 140 140 135 142 127 134 130 138 119 106 86 87 70
Johnson & Johnson 107 123 145 119 119 123 137 120 121 113 132 111 133 120 137 118 116 112
Merck & Co. Inc. 78 82 98 103 95 92 98 86 83 81 89 80 80 84 89 71 75 86
Pfizer Inc. 98 98 119 110 106 110 115 99 79 87 98 72 93 76 72 66 59 55
Regeneron Pharmaceuticals Inc. 180 163 163 158 129 129 146 94 110 137 122 106 116 136 138 98 91 68
Thermo Fisher Scientific Inc. 43 46 50 44 43 44 45 38 37 37 41 35 34 39 48 37 41 46
Vertex Pharmaceuticals Inc. 89 106 102 95 102 105 98 98 85 96 106 117 115 107 103 44 73 66

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q2 2026 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ 9.22 = 40

2 Click competitor name to see calculations.


The operating activity analysis reveals a fluctuating pattern in the management of accounts payable from March 2022 through June 2026. The data indicates periodic extensions of payment terms alternating with phases of accelerated settlement, suggesting a dynamic approach to working capital management.

Payables Turnover Ratio
The payables turnover ratio exhibits significant volatility, ranging from a low of 6.25 in December 2022 to a peak of 12.57 in June 2024. A notable contraction in turnover is observed during the fourth quarters of 2022 and 2024, indicating a slower rate of payment relative to purchases. Conversely, efficiency peaks are evident in late 2023 and mid-2024, signaling more rapid turnover of obligations.
Average Payables Payment Period
The payment period displays a cyclical trend characterized by periodic spikes in the duration of outstanding payables. The most prominent extension occurred in December 2022, reaching 58 days, followed by a secondary elevation in the second half of 2024, where the period remained constant at 49 days. These peaks are contrasted by periods of tightened payment cycles, most notably in June 2024, where the period dropped to its minimum of 29 days. From 2025 through mid-2026, the payment period fluctuated between 34 and 48 days, eventually stabilizing within a range of 38 to 40 days.

AI Ask an analyst for more


Cash Conversion Cycle

Gilead Sciences Inc., cash conversion cycle calculation (quarterly data)

No. days

Microsoft Excel
Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data
Average inventory processing period 115 114 104 105 108 103 100 101 110 102 100 105 106 102 97 78 81 81
Average receivable collection period 62 59 62 65 61 56 56 59 62 62 63 64 57 57 65 59 55 51
Average payables payment period 40 38 42 48 34 43 49 49 29 34 31 37 40 41 58 33 31 32
Short-term Activity Ratio
Cash conversion cycle1 137 135 124 122 135 116 107 111 143 130 132 132 123 118 104 104 105 100
Benchmarks
Cash Conversion Cycle, Competitors2
Amgen Inc. 208 194 216 195 200 216 222 234 270 349 441 277 285 290 273 282 267 245
Danaher Corp. 108 86 81 92 90 84 76 95 90 88 91 98 94 93 81 82 79 75
Eli Lilly & Co. 386 373 375 386 371 329 278 306 277 265 261 224 222 248 219 194 197 198
Johnson & Johnson 140 116 93 127 121 105 89 116 112 109 86 100 99 100 72 78 82 80
Merck & Co. Inc. 117 124 116 126 135 120 107 129 138 138 118 123 126 116 93 106 106 113
Pfizer Inc. 186 207 192 224 202 188 173 207 173 155 120 124 113 91 63 94 96 96
Regeneron Pharmaceuticals Inc. 453 468 539 559 585 597 586 640 607 562 555 558 564 564 584 490 420 326
Thermo Fisher Scientific Inc. 106 103 98 112 110 104 97 112 107 105 101 111 112 106 97 111 116 118
Vertex Pharmaceuticals Inc. 338 338 333 335 304 274 242 229 211 190 166 154 137 131 112 150 120 122

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q2 2026 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= 115 + 6240 = 137

2 Click competitor name to see calculations.


The cash conversion cycle exhibits a general upward trend over the analyzed period, indicating a gradual expansion in the time required to convert resource inputs into cash flows. The cycle increased from 100 days in March 2022 to 137 days by June 2026, reflecting a decrease in overall working capital efficiency.

Average Inventory Processing Period
A consistent long-term increase is observed in the time required to process inventory. Starting at 81 days in early 2022, the period climbed steadily, surpassing the 100-day threshold by March 2023 and reaching a peak of 115 days by June 2026. This upward trajectory suggests a slowing of inventory turnover, which serves as the primary driver for the extension of the total cash conversion cycle.
Average Receivable Collection Period
The collection of receivables remained relatively stable with moderate fluctuations. The period oscillated between a low of 51 days in March 2022 and a high of 65 days in December 2022. While there were periodic shifts, the metric generally maintained a range between 56 and 65 days through 2026, indicating a consistent approach to credit management and collections.
Average Payables Payment Period
Payment patterns to suppliers demonstrate significant volatility. A notable spike occurred in December 2022, reaching 58 days, followed by a contraction toward 30 days in mid-2024. Subsequent increases were observed in late 2024 and 2025, peaking at 49 and 48 days respectively. These fluctuations suggest inconsistent leverage of supplier credit or periodic strategic adjustments in payment timing.
Cash Conversion Cycle Integration
The overall cash conversion cycle was characterized by two distinct phases. From March 2022 to June 2024, the cycle expanded from 100 to 143 days, driven largely by the accumulation of inventory processing time. A temporary contraction occurred in late 2024, where the cycle dipped to 107 days due to a simultaneous increase in the payables payment period and a brief decrease in inventory processing time. However, by June 2026, the cycle returned to an elevated level of 137 days, confirming a long-term trend of reduced operational liquidity efficiency.

AI Ask an analyst for more